Expressions of miRNA-223 and miRNA-29c in breast cancer and clinical significance
Yongpeng He,Haiwei Zhang,Wanyan Tang,Lin Yi,Lixian Li,Jianting Zeng,Huiying Fang,Weiqi Nian
DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2016.06.004
2016-01-01
Abstract:Objective To investigate the expressions of microRNA (miRNA)-223 and miRNA-29c in breast cancer tissue, peritumoral tissues (2 cm from tumor margin) and breast cancer cell lines, and analyze the correlation between their expressions and clinicopathological characteristics of breast cancer. Methods For a retrospective cross-sectional study, the expressions of miRNA-223 and miRNA-29c were detected by real-time quantitative PCR in breast cancer tissues from 125 cases ( including 81 cases with complete clinicopathological data) , among which 12 cases provided peritumoral tissues ( 12 paired breast cancer tissues and peritumoral tissues), in Chongqing Cancer Institute from July 2013 to January 2014. The breast cancer cell lines included MCF-7 ( ER positive ) , MDA-MB-231 ( triple-negative ) and SKBR3 ( HER-2 positive ) . The expressions of miRNA-223 and miRNA-29c in breast cancer tissues, adjacent peritumoral tissues and breast cancer cell lines were detected by real-time quantitative PCR. The expression difference of miRNA-223 and miRNA-29c in 12 cases of breast cancer tissues and corresponding peritumoral tissues was analyzed by paired t test. The correlation between their expressions and clinicopathological parameters was detected by Pearson analysis. Independent t test was performed to analyze the correlation between their expressions and clinicopathological characteristics in 81 cases with complete clinicopathological data. The expression levels of miRNA-223 and miRNA-29c in 3 different breast cancer cell lines were compared by one-way analysis of variance and pairwise comparison was performed by LSD-t test. Results The expressions of miRNA-223 and miRNA-29c in breast cancer tissues were lower than those in peritumoral tissues (miRNA-223:2. 27±0. 75 vs 9. 34±3. 24, miRNA-29c:0. 69±0. 40 vs 2. 58±0. 75, t=6. 763, 11. 354, both P<0. 001). miRNA-223 expression was positively correlated with miRNA-29c expression in breast cancer tissues (r=0. 737, P<0. 001). The expression level of miRNA-223 was related with tumor location and miRNA-223 expression in left breast cancer was significantly higher than that in right breast cancer (t=2. 032,P=0. 046), while miRNA-29c expression was not related to tumor location (t=-0. 587,P=0. 559). Meanwhile, the expression levels of miRNA-223 and miRNA-29c in breast cancer were not correlated with patients’age, tumor diameter, lymph node metastasis, TNM staging, ER, PR, HER-2, Ki67 and p53 expression ( t=-0. 079, 0. 202; -0. 227, 0. 899; -1. 355, -0. 544; -1. 482,-0. 338; -0. 487,0. 429;0. 395,1. 432; -1. 432, -1. 318; -0. 049, -0. 307; -0. 330, 1. 234; all P>0. 050). The expression levels of miRNA-223 in breast cancer cell lines MDA-MB-231, MCF-7 and SKBR3 were 2. 16 ± 0. 28, 0. 93 ± 0. 24 and 0. 57 ± 0. 15 respectively, indicating a significant difference ( F=39. 224, P<0. 001). The expression level of miRNA-223 in breast cancer MDA-MB-231 cells was significantly higher than that in MCF-7 and SKBR3 (both P<0. 050). The expression levels of miRNA-29c in breast cancer cell lines MDA-MB-231, MCF-7 and SKBR3 were 0. 54 ± 0. 04, 0. 44 ± 0. 06 and 0. 41 ± 0. 04, respectively, indicating a significant difference (F=6. 652, P=0. 030). The expression level of miRNA-29c in MDA-MB-231 and SKBR3 cells was significantly lower than that in MCF-7 cells (P=0. 034, 0. 013). Conclusion miRNA-223 and miRNA-29c, served as potential biomarkers for breast cancer diagnosis, may be associated with molecular typing of breast cancer.